Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20640363 | 0.99 | GABRA5 (0.51) | GABRA5GABRB2HSD17B10DPP4LMNA | |
| SCHEMBL3620336 | 0.84 | GABRA5 (0.57) | GABRA5GABRB2HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL19820647 | 0.83 | HSD17B10 (0.47) | GABRA5GABRB2HSD17B10SMN1; SMN2F2 | |
| SCHEMBL3621586 | 0.83 | GABRA5 (0.55) | GABRA5GABRB2HSD17B10DPP4LMNA | |
| Hydrochloric Acid SCHEMBL20640317 | 0.82 | HSD17B10 (0.46) | GABRA5GABRB2HSD17B10SMN1; SMN2F2 | |
| Hydrochloric Acid SCHEMBL19814023 | 0.82 | HSD17B10 (0.46) | GABRA5GABRB2HSD17B10SMN1; SMN2F2 | |
| SCHEMBL14159379 | 0.82 | GABRA5 (0.54) | GABRA5GABRB2HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL2111372 | 0.82 | SMN1; SMN2 (0.58) | GABRA5GABRB2HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL20648977 | 0.81 | F2 (0.46) | GABRA5GABRB2HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL3545335 | 0.81 | F2 (0.56) | GABRA5GABRB2HSD17B10LMNAF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| WO-2019011715-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-01-17 | — | — | WO | disclosed |
| US-9309546-B2 | Genetically modified cell and process for use of said cell | PURAC BIOCHEM B.V. (NL) | 2016-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | CHKA, CHKB, NADK | GABRA5 3984/4885GABRB2 4376/4885HSD17B10 3148/4885 |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | CHKA, CHKB, NADK | GABRA5 3840/4885GABRB2 3968/4885HSD17B10 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.